These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 33024921)
21. Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer. Jacot W; Mazel M; Mollevi C; Pouderoux S; D'Hondt V; Cayrefourcq L; Bourgier C; Boissiere-Michot F; Berrabah F; Lopez-Crapez E; Bidard FC; Viala M; Maudelonde T; Guiu S; Alix-Panabières C Clin Chem; 2020 Aug; 66(8):1093-1101. PubMed ID: 32712650 [TBL] [Abstract][Full Text] [Related]
22. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Nicolazzo C; Raimondi C; Mancini M; Caponnetto S; Gradilone A; Gandini O; Mastromartino M; Del Bene G; Prete A; Longo F; Cortesi E; Gazzaniga P Sci Rep; 2016 Aug; 6():31726. PubMed ID: 27553175 [TBL] [Abstract][Full Text] [Related]
23. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004 [TBL] [Abstract][Full Text] [Related]
24. Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients. Katsarou SD; Messaritakis I; Voumvouraki A; Kakavogiannis S; Κotsakis A; Alkahtani S; Stournaras C; Martin SS; Georgoulias V; Kallergi G J Pers Med; 2022 Jan; 12(2):. PubMed ID: 35207643 [TBL] [Abstract][Full Text] [Related]
25. The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer. Kulasinghe A; Kapeleris J; Kimberley R; Mattarollo SR; Thompson EW; Thiery JP; Kenny L; O'Byrne K; Punyadeera C Cancer Med; 2018 Dec; 7(12):5910-5919. PubMed ID: 30565869 [TBL] [Abstract][Full Text] [Related]
26. PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study. Khattak MA; Reid A; Freeman J; Pereira M; McEvoy A; Lo J; Frank MH; Meniawy T; Didan A; Spencer I; Amanuel B; Millward M; Ziman M; Gray E Oncologist; 2020 Mar; 25(3):e520-e527. PubMed ID: 32162809 [TBL] [Abstract][Full Text] [Related]
27. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135 [TBL] [Abstract][Full Text] [Related]
28. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170 [TBL] [Abstract][Full Text] [Related]
29. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment. Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151 [TBL] [Abstract][Full Text] [Related]
31. Detection of PD‑L1 expression and epithelial‑mesenchymal transition of circulating tumor cells in non‑small cell lung cancer. Jiang J; Mo W; Lian X; Cao D; Cheng H; Wang H Exp Ther Med; 2024 Jul; 28(1):294. PubMed ID: 38827467 [TBL] [Abstract][Full Text] [Related]
32. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors]. Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798 [No Abstract] [Full Text] [Related]
33. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460 [TBL] [Abstract][Full Text] [Related]
34. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis. Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410 [TBL] [Abstract][Full Text] [Related]
35. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients. Liu M; Wang R; Sun X; Liu Y; Wang Z; Yan J; Kong X; Liang S; Liu Q; Zhao T; Ji X; Wang G; Wang F; Wang G; Chen L; Zhang Q; Lv W; Li H; Sun M Mol Oncol; 2020 Apr; 14(4):865-881. PubMed ID: 31981446 [TBL] [Abstract][Full Text] [Related]
37. PD-L1 Zhang L; Zhang X; Liu Y; Zhang T; Wang Z; Gu M; Li Y; Wang DD; Li W; Lin PP Cancer Lett; 2020 Jan; 469():355-366. PubMed ID: 31678168 [TBL] [Abstract][Full Text] [Related]
38. Prognosis value of circulating tumor cell PD‑L1 and baseline characteristics in patients with NSCLC treated with immune checkpoint inhibitors plus platinum‑containing drugs. Su X; Zhou C; Chen S; Ma Q; Xiao H; Chen Q; Zou H Oncol Lett; 2024 Mar; 27(3):131. PubMed ID: 38362233 [TBL] [Abstract][Full Text] [Related]
39. Gene expression profiling of circulating tumor cells captured by MicroCavity Array is superior to enumeration in demonstrating therapy response in patients with newly diagnosed advanced and locally advanced non-small cell lung cancer. Cohen EN; Jayachandran G; Gao H; Peabody P; McBride HB; Alvarez FD; Bravo PL; Qiao W; Liu S; Yao L; Lin SH; Reuben JM Transl Lung Cancer Res; 2023 Jan; 12(1):109-126. PubMed ID: 36762061 [TBL] [Abstract][Full Text] [Related]
40. Diagnostic Performance of Circulating Tumor Cells for Predicting of Hepatocellular Carcinoma in Hepatitis C Virus-High Risk Patients: Role of Liquid Biopsy. El-Mezayen HA; El -Kassas M; El-Taweel FM; Metwally FM; Ghonaim NA; Zahran RF Asian Pac J Cancer Prev; 2022 Jul; 23(7):2541-2549. PubMed ID: 35901363 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]